Cargando…
Personalized cancer therapy prioritization based on driver alteration co-occurrence patterns
Identification of actionable genomic vulnerabilities is key to precision oncology. Utilizing a large-scale drug screening in patient-derived xenografts, we uncover driver gene alteration connections, derive driver co-occurrence (DCO) networks, and relate these to drug sensitivity. Our collection of...
Autores principales: | Mateo, Lidia, Duran-Frigola, Miquel, Gris-Oliver, Albert, Palafox, Marta, Scaltriti, Maurizio, Razavi, Pedram, Chandarlapaty, Sarat, Arribas, Joaquin, Bellet, Meritxell, Serra, Violeta, Aloy, Patrick |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7488324/ https://www.ncbi.nlm.nih.gov/pubmed/32907621 http://dx.doi.org/10.1186/s13073-020-00774-x |
Ejemplares similares
-
Exploring the OncoGenomic Landscape of cancer
por: Mateo, Lidia, et al.
Publicado: (2018) -
A PanorOmic view of personal cancer genomes
por: Mateo, Lidia, et al.
Publicado: (2017) -
Recycling side-effects into clinical markers for drug repositioning
por: Duran-Frigola, Miquel, et al.
Publicado: (2012) -
HER2 + breast cancers evade anti-HER2 therapy via a switch in driver pathway
por: Smith, Alison E., et al.
Publicado: (2021) -
Drug sensitivity in cancer cell lines is not tissue-specific
por: Jaeger, Samira, et al.
Publicado: (2015)